Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 443

1.

[Metabolic disorders in renal transplant recipients].

Mikolasević I, Jelić I, Sladoje-Martinović B, Orlić L, Zivcić-Cosić S, Vuksanović-Mikulicić S, Mijić M, Racki S.

Acta Med Croatica. 2012 Jul;66(3):235-41. Croatian.

PMID:
23441539
2.

Clinicoepidemiologic study of posttransplant diabetes after living-donor renal transplant.

Elmagd MM, Bakr MA, Metwally AH, Wahab AM.

Exp Clin Transplant. 2008 Mar;6(1):42-7.

3.

Role of calcium channel blockers in diabetic renal transplant patients: preliminary observations on protection from sepsis.

Weinrauch LA, D'Elia JA, Gleason RE, Shaffer D, Monaco AP.

Clin Nephrol. 1995 Sep;44(3):185-92.

PMID:
8556835
4.

Prevalence evolution and impact of cardiovascular risk factors on allograft and renal transplant patient survival.

Díaz JM, Gich I, Bonfill X, Solà R, Guirado L, Facundo C, Sainz Z, Puig T, Silva I, Ballarín J.

Transplant Proc. 2009 Jul-Aug;41(6):2151-5. doi: 10.1016/j.transproceed.2009.06.134.

PMID:
19715859
5.

[Hypertension after kidney transplantation].

Racki S.

Lijec Vjesn. 2006 Nov-Dec;128(11-12):373-8. Review. Croatian.

PMID:
17212200
6.

Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies).

Vanrenterghem Y, Bresnahan B, Campistol J, Durrbach A, Grinyó J, Neumayer HH, Lang P, Larsen CP, Mancilla-Urrea E, Pestana JM, Block A, Duan T, Glicklich A, Gujrathi S, Vincenti F.

Transplantation. 2011 May 15;91(9):976-83. doi: 10.1097/TP.0b013e31820c10eb.

PMID:
21372756
7.

Functional and histopathologic changes in renal transplant patients with new-onset diabetes and dyslipidemia.

Borda B, Szederkényi E, Lengyel C, Morvay Z, Eller J, Marofka F, Szabó V, Takács T, Szenohradszky P, Hódi Z, Lázár G.

Transplant Proc. 2011 May;43(4):1254-8. doi: 10.1016/j.transproceed.2011.03.091.

PMID:
21620104
8.

Assessment of cardiovascular risk factors after renal transplantation: a step towards reducing graft failure.

Kumar R, Brar J, Yacoub R, Khan T, Zachariah M, Venuto R.

Transplant Proc. 2012 Jun;44(5):1270-4. doi: 10.1016/j.transproceed.2012.01.111.

PMID:
22663999
9.

Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients.

del Castillo D, Campistol JM, Guirado L, Capdevilla L, Martínez JG, Pereira P, Bravo J, Pérez R.

Kidney Int Suppl. 1998 Dec;68:S135-9.

PMID:
9839298
10.

HLA-identical sibling renal transplantation--a 21-yr single-center experience.

de Mattos AM, Bennett WM, Barry JM, Norman DJ.

Clin Transplant. 1999 Apr;13(2):158-67.

PMID:
10202612
11.

Potential cardiovascular risk factors in paediatric renal transplant recipients.

Ferraris JR, Ghezzi L, Waisman G, Krmar RT.

Pediatr Nephrol. 2006 Jan;21(1):119-25. Epub 2005 Oct 27.

PMID:
16252106
12.

Hypertension, antihypertensive agents and outcomes following renal transplantation.

Tutone VK, Mark PB, Stewart GA, Tan CC, Rodger RS, Geddes CC, Jardine AG.

Clin Transplant. 2005 Apr;19(2):181-92.

PMID:
15740553
13.

Risk factors for and management of post-transplantation cardiovascular disease.

Fellström B.

BioDrugs. 2001;15(4):261-78. Review.

PMID:
11437691
14.

Long-term consequences of different immunosuppressive regimens for renal allografts.

Isoniemi HM, Ahonen J, Tikkanen MJ, von Willebrand EO, Krogerus L, Eklund BH, Höckerstedt KV, Salmela KE, Häyry PJ.

Transplantation. 1993 Mar;55(3):494-9. Erratum in: Transplantation 1998 Sep 15;66(5):678.

PMID:
8456467
15.

Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?

Cheung CY, Liu YL, Wong KM, Chan HW, Chan YH, Wong HS, Chak WL, Choi KS, Chau KF, Shek CC, Li CS.

Nephrology (Carlton). 2008 Jun;13(3):251-5. doi: 10.1111/j.1440-1797.2007.00911.x. Epub 2008 Jan 23.

PMID:
18221256
16.

Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.

Krämer BK, Montagnino G, Del Castillo D, Margreiter R, Sperschneider H, Olbricht CJ, Krüger B, Ortuño J, Köhler H, Kunzendorf U, Stummvoll HK, Tabernero JM, Mühlbacher F, Rivero M, Arias M; European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study Group.

Nephrol Dial Transplant. 2005 May;20(5):968-73. Epub 2005 Mar 1.

PMID:
15741208
17.

Use of tacrolimus and the development of posttransplant diabetes mellitus: a Brazilian single-center, observational study.

Gnatta D, Keitel E, Heineck I, Cardoso BD, Rodrigues AP, Michel K, Garcia VD.

Transplant Proc. 2010 Mar;42(2):475-8. doi: 10.1016/j.transproceed.2010.02.021.

PMID:
20304169
18.

Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.

Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.

Nephrol Dial Transplant. 2005 Nov;20(11):2517-23. Epub 2005 Jun 28.

PMID:
15985508
19.

Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.

Sayin B, Karakayali H, Colak T, Sevmis S, Pehlivan S, Demirhan B, Haberal M.

Transplant Proc. 2009 Sep;41(7):2789-93. doi: 10.1016/j.transproceed.2009.07.094.

PMID:
19765436
20.

Impact of posttransplant diabetes mellitus on graft function in autosomal dominant polycystic kidney disease patients after kidney transplantation.

Pietrzak-Nowacka M, Safranow K, Dziewanowski K, Debska-Slizień A, Głyda M, Gołembiewska E, Jankowska M, Nowosiad M, Rutkowski B, Ciechanowski K.

Ann Acad Med Stetin. 2008;54(1):41-8.

PMID:
19127808

Supplemental Content

Support Center